L7 inks deal with ATCC
L7 Informatics has signed an agreement with the American Type Culture Collection (ATCC) to enhance the digitalization of its manufacturing and laboratory operations. Read More
Everest Medicines and AbCellera ink multiyear deal
Everest Medicines and AbCellera have entered into a multiyear collaboration and license agreement to discover therapeutic antibodies for up to 10 targets that will be selected by Everest. The initial programs will focus on targets in oncology, Everest said. Read More
Quinten Health, Aetion partner on AI for research studies
Artificial intelligence (AI) developer Quinten Health and Aetion, a real-world evidence technology provider, have formed a strategic partnership to offer an integrated range of products and services. Read More
STM working group to address image alterations, duplication
The International Association of Scientific, Technical and Medical Publishers (STM) has appointed a working group -- the Standards and Technology Committee (STEC) -- to answer questions about automatic image alteration and duplication detection in scholarly publications. Read More
Thermo Fisher releases NanoDrop Eight spectrophotometer
Thermo Fisher Scientific is releasing the NanoDrop Eight UV-Vis microvolume spectrophotometer, which replaces the NanoDrop 8000 system, the company announced. Read More
PathAI, Summit Clinical partner for NASH trial services
PathAI recently entered a partnership with Summit Clinical Research to launch a clinical trial services solution for developers of drugs to treat nonalcoholic steatohepatitis (NASH). Read More
Velocity Clinical buys 2 clinical trial networks
Velocity Clinical Research has acquired two companies that operate research trial networks: VitaLink Research and the National Research Institute. Velocity Clinical did not disclose the amount it paid for the firms. Read More
BioChain expands line of NGS-characterized biosamples
The BioChain Institute recently expanded its line of next-generation sequencing-characterized biosamples, the company announced. Read More
Pfizer-BioNTech COVID-19 vaccine safe for kids ages 5-11
Pfizer and BioNTech's COVID-19 vaccine is safe and well tolerated and showed robust neutralizing antibody responses in children between the ages of 5 and 11, according to clinical trial results. Read More
PerkinElmer acquires BioLegend for $5.25B
PerkinElmer announced it has completed its $5.25 billion acquisition of life science antibody and reagent company BioLegend, a deal first announced in July. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter